Cameroon vs Lesotho: HIV positive pregnant women receiving antiretrovirals, using

Cameroon
62.0%
in 2011
Lesotho
70.0%
in 2011
Cameroon rank
18th
Lesotho rank
16th

HIV positive pregnant women receiving antiretrovirals, using over time

  • Cameroon
  • Lesotho
020406080100200420072011

How they compare

Lesotho currently reports 70.0% against 62.0% in Cameroon, a difference of 8.0%.

That makes Lesotho's figure about 1.1 times Cameroon's.

The two have swapped places 3 times across 6 shared years of data; in 2004 it was Cameroon ahead.

Cameroon ranks 18th and Lesotho ranks 16th of 38 countries.

Lesotho has averaged higher in every one of the 2 decades both report.

Head to head by decade

Decade Cameroon Lesotho Difference Ahead
2000s 27.8% 34.4% 6.6% Lesotho
2010s 62.0% 70.0% 8.0% Lesotho

Averages of every year both report within each decade.

Frequently asked questions

Which has higher hiv positive pregnant women receiving antiretrovirals, using, Cameroon or Lesotho?
Lesotho, at 70.0% against 62.0% in Cameroon as of 2011.
What is the difference in hiv positive pregnant women receiving antiretrovirals, using between Cameroon and Lesotho?
8.0%, with Lesotho ahead.
How many years of comparable data are there for Cameroon and Lesotho?
6 years are reported by both, from 2004 to 2011.
How do Cameroon and Lesotho rank globally for hiv positive pregnant women receiving antiretrovirals, using?
Cameroon ranks 18th and Lesotho ranks 16th of 38 countries.
Where does this data come from?
http://data.unaids.org/pub/GlobalReport/2008/, published as HIV positive pregnant women receiving antiretrovirals, using WHO/UNAIDS methodology (%; high estimate). Statizoid refreshes it automatically from the source and publishes the full history for both places.

Individual pages

Share, cite or embed this page

Cite this page

Cameroon vs Lesotho: HIV positive pregnant women receiving antiretrovirals, using. Statizoid, drawing on http://data.unaids.org/pub/GlobalReport/2008/. Retrieved 13 September 2026, from https://health.statizoid.com/compare/hiv-positive-pregnant-women-receiving-antiretrovirals-using-who-unaids-methodology/cameroon/lesotho/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://health.statizoid.com/compare/hiv-positive-pregnant-women-receiving-antiretrovirals-using-who-unaids-methodology/cameroon/lesotho/">Cameroon vs Lesotho: HIV positive pregnant women receiving antiretrovirals, using</a> — Statizoid

About this data

Indicator
HIV positive pregnant women receiving antiretrovirals, using WHO/UNAIDS methodology (%; high estimate)
Unit
%; high estimate
Source
http://data.unaids.org/pub/GlobalReport/2008/
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
38 places, 216 data points, 2004–2011
Last refreshed

Percentage of HIV-infected pregnant women who received antiretrovirals to reduce the risk of mother-to-child transmission. Numerator: Number of HIV-infected pregnant women who received antiretrovirals during the last 12 months to reduce mother-to-child transmission. Denominator: Estimated number of HIV-infected pregnant women in the last 12 months. Ranges are presented for countries with low and concentrated epidemics. The purpose of this indicator is to assess progress in preventing vertical transmission of HIV. All data reflect values representing 12 month period ending December 2007 which have been reconciled between reporting country and UNAIDS/WHO/UNICEF, unless otherwise noted. All analysis of this indicator, including quoted country figures, reflect numerators which have gone through a tri agency reconciliation (UNAIDS/WHO/UNICEF) process and denominators which have been estimated directly from the UNAIDS/WHO Reference group on Estimates, Modelling and Projections methodology (Spectrum). The reconciliation process ensured all agencies reported the same country endorsed figure which was the most recent and met the definition of HIV-infected women receiving antiretroviral drugs over the last 12 months, and thus reflect a full year. Every effort was made in cases of discrepancy across the three agencies to obtain approval from the country on a final indicator value.